ARIDIS PHARMACEUTICALS INC (ARDS)

US0403341045 - Common Stock

0.3101  +0.05 (+17.91%)

After market: 0.2619 -0.05 (-15.54%)

News Image
4 months ago - Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024

LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on the discovery...

News Image
6 months ago - Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update

Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health LOS GATOS,...

News Image
9 months ago - Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals Announces $2 Million Offering

Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS), a biopharmaceutical company focused on the discovery and...

News Image
9 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time to start off trading for Tuesday with a breakdown of the biggest pre-market stock movers worth watching this morning.

News Image
9 months ago - Aridis Pharmaceuticals, Inc.

Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301

LOS GATOS, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the European...

News Image
9 months ago - Aridis Pharmaceuticals, Inc.

Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation

QIDP designation for Biologics provides FDA Priority Review status LOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc....

News Image
11 months ago - Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update

LOS GATOS, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery...

News Image
a year ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day with a breakdown of the biggest pre-market stock movers that traders need to know about for Thursday morning!

News Image
a year ago - Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q

LOS GATOS, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company,...

News Image
a year ago - Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-K

LOS GATOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical...

News Image
a year ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on Monday morning!

News Image
a year ago - Aridis Pharmaceuticals, Inc.

Aridis Provides Corporate Update

LOS GATOS, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical...